|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MTX1 |
Gene summary for MTX1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MTX1 | Gene ID | 4580 |
| Gene name | metaxin 1 | |
| Gene Alias | MTX | |
| Cytomap | 1q22 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A0A0MRK6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4580 | MTX1 | LZE2T | Human | Esophagus | ESCC | 1.47e-14 | 1.16e+00 | 0.082 |
| 4580 | MTX1 | LZE4T | Human | Esophagus | ESCC | 2.45e-09 | 2.90e-01 | 0.0811 |
| 4580 | MTX1 | LZE5T | Human | Esophagus | ESCC | 1.40e-06 | 4.15e-01 | 0.0514 |
| 4580 | MTX1 | LZE7T | Human | Esophagus | ESCC | 8.50e-22 | 9.58e-01 | 0.0667 |
| 4580 | MTX1 | LZE8T | Human | Esophagus | ESCC | 4.44e-20 | 5.42e-01 | 0.067 |
| 4580 | MTX1 | LZE20T | Human | Esophagus | ESCC | 4.88e-05 | 2.29e-01 | 0.0662 |
| 4580 | MTX1 | LZE21D1 | Human | Esophagus | HGIN | 4.41e-04 | 4.85e-01 | 0.0632 |
| 4580 | MTX1 | LZE22D1 | Human | Esophagus | HGIN | 6.34e-08 | 3.26e-01 | 0.0595 |
| 4580 | MTX1 | LZE22T | Human | Esophagus | ESCC | 2.25e-16 | 8.17e-01 | 0.068 |
| 4580 | MTX1 | LZE24T | Human | Esophagus | ESCC | 5.18e-34 | 7.13e-01 | 0.0596 |
| 4580 | MTX1 | LZE21T | Human | Esophagus | ESCC | 1.97e-09 | 6.03e-01 | 0.0655 |
| 4580 | MTX1 | LZE6T | Human | Esophagus | ESCC | 6.15e-28 | 1.01e+00 | 0.0845 |
| 4580 | MTX1 | P1T-E | Human | Esophagus | ESCC | 1.98e-11 | 5.56e-01 | 0.0875 |
| 4580 | MTX1 | P2T-E | Human | Esophagus | ESCC | 5.65e-55 | 8.48e-01 | 0.1177 |
| 4580 | MTX1 | P4T-E | Human | Esophagus | ESCC | 1.25e-50 | 9.73e-01 | 0.1323 |
| 4580 | MTX1 | P5T-E | Human | Esophagus | ESCC | 2.06e-59 | 9.43e-01 | 0.1327 |
| 4580 | MTX1 | P8T-E | Human | Esophagus | ESCC | 6.31e-48 | 7.11e-01 | 0.0889 |
| 4580 | MTX1 | P9T-E | Human | Esophagus | ESCC | 1.64e-40 | 8.21e-01 | 0.1131 |
| 4580 | MTX1 | P10T-E | Human | Esophagus | ESCC | 9.86e-34 | 5.89e-01 | 0.116 |
| 4580 | MTX1 | P11T-E | Human | Esophagus | ESCC | 2.23e-30 | 9.48e-01 | 0.1426 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000700618 | Esophagus | HGIN | mitochondrial membrane organization | 37/2587 | 116/18723 | 4.61e-07 | 2.07e-05 | 37 |
| GO:00070076 | Esophagus | HGIN | inner mitochondrial membrane organization | 16/2587 | 38/18723 | 1.82e-05 | 4.93e-04 | 16 |
| GO:004873225 | Esophagus | HGIN | gland development | 88/2587 | 436/18723 | 1.34e-04 | 2.71e-03 | 88 |
| GO:000700619 | Esophagus | ESCC | mitochondrial membrane organization | 93/8552 | 116/18723 | 2.16e-14 | 1.11e-12 | 93 |
| GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
| GO:000700713 | Esophagus | ESCC | inner mitochondrial membrane organization | 31/8552 | 38/18723 | 5.93e-06 | 6.10e-05 | 31 |
| GO:003087914 | Esophagus | ESCC | mammary gland development | 85/8552 | 137/18723 | 8.11e-05 | 6.01e-04 | 85 |
| GO:00070065 | Liver | Cirrhotic | mitochondrial membrane organization | 57/4634 | 116/18723 | 1.13e-08 | 4.29e-07 | 57 |
| GO:004873212 | Liver | Cirrhotic | gland development | 154/4634 | 436/18723 | 4.03e-07 | 9.42e-06 | 154 |
| GO:00070073 | Liver | Cirrhotic | inner mitochondrial membrane organization | 19/4634 | 38/18723 | 6.75e-04 | 5.06e-03 | 19 |
| GO:005087812 | Liver | Cirrhotic | regulation of body fluid levels | 118/4634 | 379/18723 | 2.65e-03 | 1.55e-02 | 118 |
| GO:000700612 | Liver | HCC | mitochondrial membrane organization | 80/7958 | 116/18723 | 7.09e-09 | 1.81e-07 | 80 |
| GO:004873222 | Liver | HCC | gland development | 242/7958 | 436/18723 | 2.26e-08 | 5.28e-07 | 242 |
| GO:000700711 | Liver | HCC | inner mitochondrial membrane organization | 28/7958 | 38/18723 | 9.60e-05 | 8.34e-04 | 28 |
| GO:005087822 | Liver | HCC | regulation of body fluid levels | 191/7958 | 379/18723 | 1.06e-03 | 6.11e-03 | 191 |
| GO:00308795 | Liver | HCC | mammary gland development | 75/7958 | 137/18723 | 2.52e-03 | 1.22e-02 | 75 |
| GO:00075951 | Liver | HCC | lactation | 29/7958 | 47/18723 | 6.16e-03 | 2.52e-02 | 29 |
| GO:000700610 | Oral cavity | OSCC | mitochondrial membrane organization | 85/7305 | 116/18723 | 6.29e-14 | 3.40e-12 | 85 |
| GO:004873220 | Oral cavity | OSCC | gland development | 226/7305 | 436/18723 | 2.78e-08 | 5.39e-07 | 226 |
| GO:00070075 | Oral cavity | OSCC | inner mitochondrial membrane organization | 27/7305 | 38/18723 | 6.23e-05 | 5.08e-04 | 27 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MTX1 | SNV | Missense_Mutation | rs200446524 | c.895C>T | p.Arg299Trp | p.R299W | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MTX1 | SNV | Missense_Mutation | c.416N>C | p.Lys139Thr | p.K139T | protein_coding | tolerated_low_confidence(0.4) | benign(0.076) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | ||
| MTX1 | insertion | Frame_Shift_Ins | novel | c.480_481insG | p.Trp163LeufsTer69 | p.W163Lfs*69 | protein_coding | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
| MTX1 | SNV | Missense_Mutation | novel | c.834N>T | p.Glu278Asp | p.E278D | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| MTX1 | SNV | Missense_Mutation | rs776764435 | c.1031C>T | p.Ala344Val | p.A344V | protein_coding | deleterious(0.04) | possibly_damaging(0.908) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MTX1 | SNV | Missense_Mutation | novel | c.779N>A | p.Thr260Asn | p.T260N | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MTX1 | SNV | Missense_Mutation | rs201017167 | c.682T>C | p.Tyr228His | p.Y228H | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MTX1 | SNV | Missense_Mutation | novel | c.1020N>A | p.Phe340Leu | p.F340L | protein_coding | deleterious(0.01) | probably_damaging(0.917) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| MTX1 | SNV | Missense_Mutation | novel | c.766G>A | p.Val256Met | p.V256M | protein_coding | tolerated(0.05) | possibly_damaging(0.596) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| MTX1 | SNV | Missense_Mutation | c.994N>G | p.Gln332Glu | p.Q332E | protein_coding | tolerated(0.06) | possibly_damaging(0.539) | TCGA-B5-A11R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |